U.S. Markets closed

MiMedx Group, Inc. (MDXG)

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Add to watchlist
16.52+0.41 (+2.55%)
At close: 4:00PM EDT
People also watch
OSIRHALONEOMACKTGTX
Full screen
Previous Close16.11
Open16.08
Bid9.00 x 300
Ask21.50 x 100
Day's Range15.71 - 16.88
52 Week Range6.94 - 17.36
Volume1,992,103
Avg. Volume1,262,057
Market Cap1.86B
Beta0.73
PE Ratio (TTM)118.00
EPS (TTM)0.14
Earnings DateOct 25, 2017 - Oct 30, 2017
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est15.00
Trade prices are not sourced from all markets
  • PR Newswire19 hours ago

    MiMedx Signs Definitive Agreement to Divest Stability Biologics Subsidiary as Part of Company's Strategic Focus on Biopharma

    MARIETTA, Ga., Aug. 18, 2017 /PRNewswire/ -- MiMedx Group, Inc. (MDXG), the leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizing human placental tissue allografts and patent-protected processes for multiple sectors of healthcare, announced today that it has signed a definitive agreement with the former stockholders of Stability Inc. to divest the Company's subsidiary, Stability Biologics LLC (f/k/a Stability Inc.) back to those stockholders. The recent announcement by the Company to transition into a biopharmaceutical company was an impetus for this divestiture initiative.  Acquired by MiMedx in January 2016, Stability Biologics developed and processed bioactive bone graft products and tissue allografts including structural/particulate bone, structural allografts, demineralized bone matrix (DBM), skin products for burns and traumatic wound care, and Physio®, a bone grafting material.

  • PR Newswire2 days ago

    MiMedx Provides Update on Litigation with Terminated Employees

    MARIETTA, Ga., Aug. 17, 2017 /PRNewswire/ -- MiMedx Group, Inc. (MDXG), the leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics utilizing human placental tissue allografts with patent-protected processes for multiple sectors of healthcare, provided an update on its litigation with certain former employees. As previously disclosed in the Company's quarterly report on Form 10-Q as filed with the Securities and Exchange Commission on July 31, 2017, the Company filed lawsuits against certain former employees on December 13, 2016 for, among other things, selling competing products while full-time employees of MiMedx. The Company has already been successful in obtaining court orders enforcing the non-compete and other restrictive covenants against two of the former employees.

  • Forbes3 days ago

    Three Breakouts, And One Possible Breakdown In Cummins

    Three stocks breaking out of consolidation patterns lead our charts to watch today, while one trending lower is highlighted as a potential short.